Presentation 1 by Elizabeth Schnaubelt, MD, Global Tuberculosis Branch Division of Global HIV and TB

Manufacturing XDR TB: Timing of Acquired Resistance to Fluoroquinolones and Second-line Injectable Drugs during MDR TB Treatment in 9 Countries, 2005–2010, Preserving Effective TB Treatment Study (PETTS)

To view this presentation click here.


Presentation 2 by Isaac Chikwanha, MD, TB/HIV/HCV advisor, Access Campaign, MSF Geneva

The Role of Policy Adoption and Implementation for Elimination of MDR-TB

To view this presentation click here.


Presentation 3 by Gavin Churchyard, (MBBCh, FCP (SA), FRCP (Edin), MMED, PhD) Co-Chair of PHOENIx Feasibility Study and Main Trial

Accessing MDR-TB exposed Households: the PHOENiX MDR-TB Feasibility Study

To view this presentation click here.


Presentation 4 by Emily A. Kendall, MD Assistant Professor, Infectious Diseases, Johns Hopkins University School of MedicineMDR-TB

Elimination: What will it cost?

To view this presentation click here.